Share
Destabilization of Abnormal Methylation Enzymes to Combat Cancer
Ming C. Liau
(Author)
·
Jai-Hyun Kim
(Author)
·
John P. Fruehauf
(Author)
·
LAP Lambert Academic Publishing
· Paperback
Destabilization of Abnormal Methylation Enzymes to Combat Cancer - C. Liau, Ming ; Kim, Jai-Hyun ; Fruehauf, John P.
Choose the list to add your product or create one New List
✓ Product added successfully to the Wishlist.
Go to My Wishlists
Origin: U.S.A.
(Import costs included in the price)
It will be shipped from our warehouse between
Monday, July 29 and
Wednesday, August 14.
You will receive it anywhere in United Kingdom between 1 and 3 business days after shipment.
Synopsis "Destabilization of Abnormal Methylation Enzymes to Combat Cancer"
The therapeutic end point of destabilization of abnormal methylation enzymes is terminally differentiated cells. This end point is compatible with the end point on the therapy of hematological cancers. It can fit in on the therapy of hematological cancers, but it will not be easy for the acceptance on the therapy of solid cancers. In combination with surgery, or cytotoxic chemotherapy to pursue the end point of tumor disappearance is perhaps an easy way out. Different end points, however, have to be sought to legitimate differentiation therapy. End point of the disappearance of circulating cancer stem cells, or restoration of plasma/urine peptide ratios to those of healthy people are valid, but need careful studies before being accepted as valid end points.
- 0% (0)
- 0% (0)
- 0% (0)
- 0% (0)
- 0% (0)
All books in our catalog are Original.
The book is written in English.
The binding of this edition is Paperback.
✓ Producto agregado correctamente al carro, Ir a Pagar.
